LoginSignup
Editas Medicine logo

Editas Medicine Stock

StockStock
ISIN: US28106W1036
Ticker: EDIT
US28106W1036
EDIT

Price

Frequently asked questions

What is Editas Medicine's market capitalization?

The market capitalization of Editas Medicine is $272.41M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Editas Medicine?

Editas Medicine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.562. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Editas Medicine's stock?

Currently, 18 analysts cover Editas Medicine's stock, with a consensus target price of $14.86. Analyst ratings provide insights into the stock's expected performance.

What is Editas Medicine's revenue over the trailing twelve months?

Over the trailing twelve months, Editas Medicine reported a revenue of $61.76M.

What is the EBITDA for Editas Medicine?

Editas Medicine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$222.63M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Editas Medicine?

Editas Medicine has a free cash flow of -$191.36M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Editas Medicine's stock?

The 5-year beta for Editas Medicine is 1.96. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Editas Medicine have, and what sector and industry does it belong to?

Editas Medicine employs approximately 265 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Editas Medicine's shares?

The free float of Editas Medicine is 82.28M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $272.41M

5Y beta

 1.96

EPS (TTM)

 -$2.562

Free Float

 82.28M

Revenue (TTM)

 $61.76M

EBITDA (TTM)

 -$222.63M

Free Cashflow (TTM)

 -$191.36M

Pricing

1D span
$3.046$3.316
52W span
$2.70$11.69

Analyst Ratings

The price target is $14.86 and the stock is covered by 18 analysts.

Buy

8

Hold

9

Sell

1

Information

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

265

Biotechnology & Drugs

Health Care

Identifier

ISIN

US28106W1036

Primary Ticker

EDIT

Knockouts

Join the conversation
Sign upLogin